Karyopharm Reports Q1 2025 Revenue of $30.0M, Net Loss of $23.5M; Phase 3 SENTRY Trial Passes Futility Analysis

Karyopharm Therapeutics Inc.

2025-Q1 EPS reported -$2.77 revenue$30,015,000

Total revenue $30.0M; U.S. XPOVIO net product revenue $21.1M, impacted by $5.0M increase in product return reserve for expired 80 mg and 100 mg units.
Phase 3 SENTRY trial (selinexor + ruxolitinib) passed futility analysis, is ~80% enrolled; target enrollment expected June/July 2025.
Phase 2 XPORT-MF-035 data: selinexor monotherapy achieved SVR25 in 67% of evaluable patients vs 38% with physician's choice.
Reaffirms full-year 2025 guidance: total revenue $140M–$155M, U.S. XPOVIO net product revenue $115M–$130M.
Cash, cash equivalents and investments $70.3M as of March 31, 2025; exploring alternatives to extend cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.